ABTAbbott Laboratories

$114.10

$82.5652 weeks$134.49

Price

$114.10-11%1Y

1M+13%1Y-11%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Above average

7/10

Value53

Quality86

Momentum35

Growth52

Strongest Quality, weakest Momentum · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott’s* principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. On November 19, 2025, Abbott entered into a definitive agreement to acquire Exact Sciences Corporation (Exact Sciences), which is expected to enable Abbott to enter the cancer diagnostics market. The acquisition is subject to customary closing conditions, including the approval of Exact Sciences shareholders and obtaining the required regulatory clearances.

In the company’s own words · 10-K filed Feb 20, 2026 · SEC EDGAR

P/E (TTM)31.9

Market Cap$153.99B

1Y Return-11%

5Y Return+3.2%

Business segments

Q2 2026 · $1.28B

The company’s own SEC segment disclosure.

Nutritional Products$525.0M41%
Diagnostic Products$377.0M29%
Medical Devices$377.0M29%

Abbott Laboratories (ABT) reported revenue of $11.2B in Q1 2026 (quarter ended March 31, 2026), up 7.8% from the same quarter a year earlier. That came with a gross margin of 56% and net income of $1.08B (9.6% of revenue). For the full year FY2025, revenue was $44.3B (+5.7% year on year) and net income $6.52B. Its largest segment in 2026-Q2 was Nutritional Products at $525M, 41% of the disclosed total, just ahead of Diagnostic Products at 29%.

Raw charts

11 series · TTM

As reported to the SEC, without any scoring.

Medical Devices

Ranks #16 of 35 by Smart Score